Carboplatin Intensified Chemotherapy for TRIple NEgative Breast Cancer(CITRINE)
Status:
Recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
This is a prospective, single center, randomized, open-labled stage III clinical trial
comparing the efficacy and safety of anthracyclin followed by weekly paclitaxel versus
dose-dense anthracyclin followed by weekly paclitaxel versus dose-dense anthracyclin followed
by weekly paclitaxel combined with carboplatin for high-risk, triple-negative early breast
cancer.